The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an ...

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...

The AHA Oct. 24 announced it has been awarded a nearly $1.5 million grant from the Centers for Disease Control and Prevention ...

The CDC now says everyone 50 to 64 years old should get a pneumococcal vaccine to help protect against serious illnesses like pneumonia, meningitis, and bloodstream infections.

All adults aged 50 and older should receive a vaccine against bacteria that can cause pneumonia and meningitis, federal ...

The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

The CDC recommends that immunocompromised people age 65 and older should get a second dose of the 2024-2025 COVID vaccine.

Each year, the U.S. sees roughly 30,000 cases of invasive pneumococcal disease, which includes blood infections, brain and ...

The drug was also evaluated in the PURPOSE-1 trial (NCT04994509), which compared lenacapavir as PrEP to alternative daily PrEP with Truvada or Gilead’s Descovy (emtricitabine and tenofovir ...

The drug was also evaluated in the PURPOSE-1 trial (NCT04994509), which compared lenacapavir as PrEP to alternative daily PrEP with Truvada or Gilead’s Descovy (emtricitabine and tenofovir alafenamide ...

The Centers for Disease Control and Prevention (CDC) has announced the five health departments that will receive federal funding to provide generic pre-exposure prophylaxis (PrEP) to prevent HIV as ...

The move involves the company’s long-acting cabotegravir (CAB LA), a PrEP medication made from one of the active ingredients in the company’s HIV treatment Cabenuva. The drug was the first ...